drugset
drugset / Trial / NCT01952132

Safety, Tolerability, and Pharmacokinetics of OMS643762 in Psychiatrically Stable Schizophrenia Subjects

NCT01952132 ↗

Phase 2 Completed 40 enrolled Omeros Corporation
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine the safety, tolerability and pharmacokinetics of OMS643762 (the study drug) in psychiatrically stable schizophrenia patients.

Timeline

Start
2013-09
Primary completion
2014-04
Completion
2014-04

Drugs

EvaluationDrugModalityDoseRoute
Subject OMS643762 Unknown — Oral

Indications

schizophrenia